The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

CelLBxHealth plc

 ("CelLBxHealth" or the "Company")

Issue of Share Options

Guildford, UK and Plymouth Meeting, U.S. - 16 July 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that, the Nominations/Remuneration Committee has approved the issue of up to 50,000,000 Share Options under its existing share option plans to employees (the "Share Options") including 11,400,000 Share Options to Michelle Munson, Chief of Staff and a Person Discharging Managerial Responsibility ("PDMR").

Share Options are issued to align the interest of employees with shareholders and help motivate, reward and retain them. The allocation of Share Options approved by the Nominations/Remuneration Committee takes into account the significant contribution from the senior management team and wider staff to the task of delivering against the revised business strategy, and, in particular, to converting the commercial pipeline into sustainable revenue growth. This, in turn, would be expected to deliver increased shareholder value.

Following the issue of these options, the Company will have outstanding options over a total of up to 55,845,000 Ordinary Shares, representing approximately 4.9% of its issued and to be issued share capital.

The exercise price for the Share Options is 1.35 pence per Ordinary Share, the Company's closing mid-market share price per Ordinary Share on 15 July 2026, being the latest practicable date prior to this announcement. The Share Options are subject to certain service and/or performance conditions over a three-year period.

All of these Share Options have performance conditions as set out below:

·      Time-based vesting: One-third (1/3) of the Share Options will vest on the first anniversary of the grant date. The remaining time-based options will then vest in equal quarterly instalments of one-twelfth (1/12) over the following two years.

·      Performance-based vesting: The final portion of the Share Options (those scheduled to vest during quarters 7 to 12 after the grant date) will only vest if, in addition to the employee remaining continuously employed, the Company's share price closes at or above 2.5p on any 10 out of 20 consecutive trading days at any point before the end of the three-year period. 

​

For further information:

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial focus span three revenue streams - Product Sales of the Parsortix platform and consumables through CRO and clinical lab partnerships, Laboratory Services including clinical trial support and assay development delivered from a GCLP-compliant UK facility, and Lab Developed Tests (LDTs), pursued through a combination of strategic partnerships and in-house development.

For more information, visit https://cellbxhealth.com/

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR") and persons closely associated with them ("PCA")

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail in respect of the transaction as described above.